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ABSTRACT 
Aberrant tau phosphorylation is a hallmark in Alzheimer’s disease (AD), believed to promote 
formation of paired helical filaments, the main constituent of neurofibrillary tangles in the 
brain. Whilst cerebrospinal fluid (CSF) levels of total tau and tau phosphorylated at threonine 
residue 181 (pThr181) are established core biomarkers for AD, the value of alternative 
phosphorylation sites, that may have more direct relevance to pathology, for early diagnosis 
is not yet known, largely due to their low levels in CSF and lack of standardized detection 
methods. 
To overcome sensitivity limitations for analysis of phosphorylated tau in CSF, we have 
applied an innovative mass spectrometry (MS) workflow, TMTcalibrator™, to enrich and 
enhance the detection of phosphoproteome components of AD brain tissue in CSF, and 
enable the quantitation of these analytes. We aimed to identify which tau species present in 
the AD brain are also detectable in CSF and which, if any, are differentially regulated with 
disease. 
Over 75% coverage of full length (2N4R) tau was detected in the CSF with 47 
phosphopeptides covering 31 different phosphorylation sites. Of these, 11 phosphopeptides 
were up-regulated by at least 40%, along with an overall increase in tau levels in the CSF of 
AD patients relative to controls. 
Use of the TMTcalibrator™ workflow dramatically improved our ability to detect tau-derived 
peptides that are directly related to human AD pathology. Further validation of regulated tau 
peptides as early biomarkers of AD is warranted and is currently being undertaken. 
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INTRODUCTION 
Protein structure and function is modulated by post-translational modifications, the most 
common modification being protein phosphorylation at serine, threonine and tyrosine 
residues. It is estimated that one third of all cellular proteins are phosphorylated to some 
degree, and these phosphorylation events are involved in many regulatory functions 
including, but not exclusive to, structural integrity, signal transduction, differentiation and 
proliferation, metabolism and degradation [1]. The reversible phosphorylation of a protein 
substrate is continuously modulated by protein kinases and phosphatases, and dysregulation 
of this tight control is a feature of many diseases (ref to a suitable review?).  In cancer, where 
signaling pathways involved in cell cycle control, such as apoptosis and proliferation, are 
disrupted, there is a long history of understanding the role played by abnormal 
phosphorylation which has led to many new drug targets (Reference and example here?).  
The modulation of phosphorylation events in disease is therefore a key area of research.  
Aberrant phosphorylation of a number of proteins is also characteristic of Alzheimer’s 
disease (AD) molecular pathogenesis. AD is a progressive neurodegenerative disorder 
accounting for more than 60% of all dementia cases, and affecting an estimated 36 million 
individuals worldwide (Alzheimer’s association). The pathological hallmarks of AD include 
plaques, comprised of the amyloid-beta (amyloid-β) protein, and neurofibrillary tangles 
(NFTs) containing hyperphosphorylated forms of the microtubule associated protein tau in 
specific brain regions [2, 3]. Tau exemplifies the aberrant phosphorylation in AD as the 
protein molecules become hyperphosphorylated and in this hyperphosphorylated state, tau 
aggregates into paired helical filaments (PHF), the main constituent of the pathological NFTs 
(REF = Grunke-Iqbal 1986?). This altered phosphorylation is likely to be the result of 
dysregulation of the kinases and phosphatases that modulate the phosphoproteome. The 
analysis of the global phosphoproteome alterations in AD (and other diseases) is therefore an 
important area of research that needs to be explored.   
Mass spectrometry (MS) based approaches are ideal for detecting phosphorylation events. 
Liquid chromatography–tandem MS (LC-MS/MS) based workflows have been employed to 
identify proteins and their phosphopeptides from a range of sample types. Phosphopeptides 
only represent a small proportion of peptides generated by tryptic digestion of a complex 
sample, therefore pre-fractionation and enrichment techniques are required to reduce the 
complexity and enhance the detection of low abundant proteins and phosphorylation events 
alongside the more easily detectable high abundant proteins. 
The guidelines published by the National Institute of Health [4], indicate that ideally 
biomarkers should be present in readily accessible samples such as plasma or CSF, and also 
should be directly derived from the diseased tissue. A complicating issue is that such  
potential biomarkers are present in very low abundance in CSF and even lower amounts in 
plasma. Furthermore, the wide concentration span of plasma and CSF proteins and the 
predominance of plasma albumin and other high-abundant proteins limits the detection of 
novel biomarker candidates that may aid diagnosis of disease, help monitor effects of 
treatment in trials and track disease progression. Some studies using mass spectrometry 
(Gobom) or HPLC separation of CSF proteins followed by SDS-PAGE and Western blotting 
using different tau antibodies (Meredith) indicate that tau in CSF is processed to shorter 
fragments before being released to the CSF, with the N-terminus and mid-domain of the 
protein being most abundant. However, further studies using approaches with high analytical 
sensitivity are needed to fully characterize CSF tau, especially its phosphorylated forms, to 
fully explore the biomarker potential of phosphorylated tau species in the CSF. Currently, the 
CSF proteins widely accepted as the core biomarkers for AD include total tau levels and tau 
phosphorylated at threonine (Thr) residue 181 (pThr181) [5].  Despite the wide use of 
pThr181 as a measure correlating with disease severity, the phosphorylation of tau in the AD 
brain is known to extend far beyond this one site of interest, with hyperphosphorylation of tau 
in the brain characteristic of disease. There are also neurodegenerative diseases other than 
AD (e.g., progressive supranuclear palsy and some forms of frontotemporal dementia) that 
are characterized by NFT pathology but intriguingly, these are most often normal in regards 
to pThr181 tau concentrations in CSF (Blennow K et al., Nature Rev Neurol 2010). 
Potentially, other tau phosphoforms are released into the CSF in these diseases. Previous 
attempts to use MS workflows to detect tau species in the CSF have proven problematic, with 
limited observations of phosphorylated tau peptides detected [6, 7]. The challenge is how to 
find these low abundant peptides in a biofluid with a high protein dynamic range, and hyper-
abundant proteins such as albumin. To answer this question, we have applied a novel Tandem 
Mass Tag® (TMT®) MS approach. TMTcalibrator™ is a tissue-enhanced workflow, 
combining tissue and peripheral fluid proteomics to allow for the broadest peptide coverage 
of analytical samples. It was developed to detect and effectively quantify the expression of 
low abundant peptides and proteins in complex biological samples, including CSF. The 
approach combines high pH reverse phase chromatography to fractionate the sample, TMT® 
isobaric labelling to allow six samples to be analyzed simultaneously alongside a 4 point 
tissue calibrator, two separate phosphopeptide enrichment techniques in parallel, and 
increased liquid chromatography separation using a 50cm column and long MS gradient 
(Russell CL, unpublished). In addition to analyzing phosphopeptides enriched by two 
separate techniques, we also analyze the un-enriched (predominately non-phosphorylated) 
peptides for comprehensive profiling of a tissue or peripheral fluid sample. In order to 
enhance the MS data acquisition of the low abundant peptides in the analytical samples of 
interest, the 4-point calibrator is incorporated into each analysis, made possible by the use of 
TMT® labels. TMTcalibrator™ has been designed to ensure the calibrator proteins dominate 
the overall protein content of the TMT®10plex sample. As we are limited by the amount of 
protein that can be injected onto the analytical LC column, a balance between dominant 
calibrator and analytical samples must be achieved. We designed the 4-point 
TMTcalibrator™ to be spiked into the total combined analytical samples at a ratio of 
1:4:6:10.  These are arbitrary values allowing us to determine a suitable protein load from the 
six samples for analysis.  The six individual CSF samples are then combined, after separate 
TMT® labelling, at a 2x:2x:2x:2x:2x:2x ratio, falling within the 4-point calibrator range.  The 
overall dominance of the calibrator signals in the TMT® 10plex ensures the vast majority of 
peptides detected are from tissue-derived proteins. During MS acquisition, where a peptide is 
present both in the calibrator tissue and the body fluids we obtain both the peptide sequence 
and quantitative TMT® reporter ion signals from all 10 samples within the same MS/MS 
spectrum. This allows us to detect peptides that would otherwise be lower than the limit of 
detection for standard data-dependent acquisition, and results in a list of peptides that are 
common to the calibrator and the analytical samples. 
To investigate the tau species present in the CSF we included a TMTcalibrator™ approach 
with phosphopeptide enrichment. For this study we used post mortem brain tissue from AD 
patients with known Braak V/VI classification, and analyzed 3 CSF samples from non-AD 
controls and 3 CSF samples from biochemically confirmed AD patients.  The aim was to use 
the proteins present in the brain tissue (the calibrator) to trigger the MS/MS acquisition 
allowing detection of any tau peptides present in the CSF samples that are common to the AD 
brain material. In addition to detection, the use of TMT® labelling also allowed us to 
determine any regulation of the tau peptides detected in the CSF between AD patients and 
control individuals, albeit in a small cohort. 
 
MATERIALS AND METHODS 
Cerebrospinal fluid samples – CSF samples were from patients who sought medical advice 
because of cognitive impairment. Patients were designated as normal or AD according to 
CSF biomarker concentrations using cutoffs that are 90% sensitive and specific for AD [8]: 
total tau >350 ng/L, phospho-tau >80 ng/L and Aβ42 <530 ng/L. None of the biochemically 
normal subjects fulfilled these criteria. CSF total tau, phospho-tau and Aβ42 levels were 
determined using INNOTEST enzyme-linked immunosorbent assays (Fujirebio, Ghent, 
Belgium) by board-certified laboratory technicians according to protocols approved by the 
Swedish Board for Accreditation and Conformity Assessment (SWEDAC). The study was 
approved by the regional ethics committee at the University of Gothenburg. The protein 
concentration of the brain lysate was estimated by Bradford protein assay. Include analysis of 
serum as a negative control? 
Post Mortem Brain Tissue – Brain tissue samples were received from the University of East 
Finland. Three frozen tissue samples from inferior temporal cortex samples were dissected 
from larger frozen tissue sections. Samples were selected according to neurofibrillary tangle 
(NFT) pathology (Braak staging) and represent Stages V and VI of AD-related NFT 
pathology. Frozen brain tissue was lysed in 8M urea, 75mM NaCl, 50mM Tris (pH 8.2) with 
phosphatase and protease inhibitors added, before sonication (20 x 1sec 20% amplitude) on 
ice and centrifuged at 12,500g for 10mins at 4°C. The protein concentration of the brain 
lysate was estimated by Bradford protein assay. 
In-Solution Tryptic Digest and TMT® labelling – Following solubilization and denaturation 
in 100mM TEAB buffer and 0.1% SDS, the CSF samples and the AD brain tissue (calibrator) 
were reduced with 1mM TCEP at 55 °C for 60 min and alkylated with 7.5mM iodoacetamide 
at room temperature for 60 min. Trypsin was used for digestion at an approximate 1:25 
weight ratio of trypsin-to-total protein and incubated at 37 °C overnight (~18 h). Following 
digestion, the peptides were labeled with one of the TMT®10plex reagents at 15mM and 
incubated for 60 min at room temperature. To quench the TMT® reaction 0.25% 
hydroxylamine was added to each sample and incubated for 15 min. The samples were then 
combined as detailed in the text and incubated for a further 15 min and desalted on RP18 
columns.  
Fractionation and Phosphopeptide Enrichment – The TMT®10plex was split into two equal 
aliquots and both fractionated by high pH reverse phase fractionation (Thermo Fisher 
Scientific kit, product number 84868) into 8 fractions. These were pooled into 4 fractions. A 
small portion of each fraction was removed for analysis of un-enriched (predominantly non-
phosphorylated) peptides, and the remainder enriched for phosphopeptides using either 
Immobilized Metal Affinity Columns (IMAC) or Titanium dioxide (TiO2). Following 
enrichment the corresponding enriched fractions from IMAC enrichment and TiO2 
enrichment were pooled, to generate 4 fractions, and cleaned up prior to MS using Graphite 
Spin Columns (Thermo Fisher Scientific). For MS analysis the sample was resuspended in 
2% ACN + 0.1% formic acid. 
LC-MS/MS - Quantitative analysis was performed using an Orbitrap Fusion Tribrid mass 
spectrometer (Thermo Fisher Scientific) in the positive mode with EASYnLC1000 system 
and a 50cm EASY-Spray column (Thermo Fisher Scientific). The column temperature was 
maintained at 40°C, and the peptides were separated at a flow rate of 200 nL/min. Peptides 
were eluted from the column over a 180 min gradient, from 10% to 30% solvent B 
(acetonitrile with 0.1% formic acid) in 160 min, followed by an increase to 100% solvent B 
in 10mins, which was held for a further 10mins. Solvent A was water with 0.1% formic acid.  
Wash and blank LC–MS/MS runs preceded the analysis and wash runs in between fractions.  
A Top Speed HCD method with a 3 second cycle time was utilized and the parameters were 
as follows: MS; Spray voltage: 2000V; ion transfer tube temperature: 275 °C; detector: 
Orbitrap; scan range (m/z): 400-1400; resolution: 120000; AGC target: 5x105. MS/MS: HCD; 
Isolation mode: quadropole; collision energy: 35%; detector: Orbitrap; Resolution: 30000; 
AGC target: 1x104.  
Peptide Identification and Quantification – LC-MS/MS data was initially processed within 
Proteome Discoverer (PD) v1.4 (Thermo Scientific) using the Spectrum Files node.  
Spectrum selector was set to default and the SEQUEST HT node was set up to search data 
against the Uniprot Homo sapiens FASTA database (taxon ID 9606 - Version September 
2014). The reporter ions quantifier node was set up to measure the raw intensity values for 
TMT® 10plex monoisotopic ions (126, 127N, 127C, 128N, 128C, 129N, 129C, 130N, 130C, 
131). Oxidation (M), phosphorylation (S, T, Y), and deamidation (N, Q) were set as variable 
modifications. Static modifications included carbamidomethylations (C) and TMT10 (N-
terminus and K). 1% FDR and 1 x Rank 1 peptide per protein filters were applied and all raw 
intensity values exported to an Excel text file for downstream processing and filtering using 
in-house software.  
Data Normalization and analysis – TMT® reporter ion intensities for every PSM across the 6 
analytical samples within a TMT® 10plex set were normalized using the sum scaling 
technique [9-11] to minimize the effect of experimental bias and systematic errors on 
quantitative peptide quantitative values. The TMT® reporter ion intensities of the 4 calibrator 
channels were scaled using correction factors computed based on expected ratios relative to 
129C channel in each TMT® 10plex set. To measure a correspondence between expected 
calibrator signal intensities to observed calibrator signal intensities a linear model was fitted 
and applied to every peptide spectral match (PSM). Corresponding R2 (coefficient of 
variance) values were computed for each PSM. Post sum-scaling, peptide level intensities 
were determined by summing all normalized PSM intensities specific to a peptide sequence. 
Protein level quantification was determined by computing the median value of log2 peptide 
ratios. These peptide level ratios were determined as the median of sum-scaled and 
normalized peptide intensities across all 6 analytical samples within a TMT® 10plex. Protein 
level quantitation was specific to a protein accession ID, distinguishing between different 
isoforms. Statistical analysis was carried out using a two-sample T test. All data pre-
processing steps were performed using in house R scripts (R version 3.1.2 - "Pumpkin 
Helmet"). 
RESULTS 
TMTcalibrator™ with phosphopeptide enrichment provides broad coverage of the analytical 
samples of choice with the unique ability to match tissue and body fluid expression of 
identical peptides and proteins. In this study, over 34,000 unique un-phosphorylated peptides 
were observed. In addition, more than 11,000 unique phosphopeptides were detected and 
quantified in our dataset, mapping to more than 11,500 phosphosites. These peptides 
correspond to over 19,000 proteins, which match in excess of 4,000 protein groups.  
We explored this extensive dataset for the presence of peptides aligned to the sequence of 
human tau 441 (accession number P10636-8). Considering all tau peptides we achieved 86% 
coverage of the protein. These peptides matched across the entire sequence of the protein, 
including peptides at both the C and N-termini (Figure 1).  In total, we detected 168 unique 
tau peptides including 115 phosphopeptides, present in at least one of the CSF samples or in 
the brain tissue analyzed. To determine which of these are common to both the brain material 
and the CSF samples, the dataset was filtered based on the presence of a signal in the 
individual TMT® reporter ion channels. When missing values were removed, we found 87 tau 
peptides covering 76.8% of tau 441, that were present in all 10 TMT® channels, meaning 
these peptides were detectable in all six CSF samples analyzed, and in the 4-point brain lysate 
calibrator. Peptides were detected spanning the majority of the sequence, including the C- 
and N-termini, and the middle region.  Residues 127 – 155 and 291 – 321 were the main 
regions under-represented in the dataset, but this is likely due to a high number of tryptic 
cleavage sites resulting in very small peptides that are not detectable. We also identify a large 
peptide that is specific to isoform 1 of tau (758 residues, accession number P10636-1) 
indicating the presence of this tau isoform in the CSF. 47 of the 87 peptides detected in all 10 
channels were phosphorylated (Table 1), representing the most comprehensive detection of 
phosphorylated tau in CSF to date. Phosphorylation was seen at multiple sites (Table 1), with 
singly and multiply phosphorylated tau peptides present. In total we observed 31 different tau 
phosphosites that were annotated with a high confidence score (>75%) by the PhosphoRS 
tool embedded within the Proteome Discoverer software, 20 of which were present in all of 
the samples analyzed (as shown in Table 1 alongside peptide sequence). Phosphosites 
annotated with a question mark (?) could not be confidently assigned to a single amino acid 
residue within that peptide sequence. Site localization within the phosphopeptide is therefore 
ambiguous in these instances. Add negative control data (serum)? 
A benefit of using TMT® to analyze multiple samples simultaneously is that the relative 
levels of peptides and proteins detected between sample groups can be accurately determined. 
This allows us to compare the levels of the tau peptides and phosphopeptides detected in the 
CSF of non-AD individuals with the levels seen in the AD CSF patients. Following 
bioinformatics processing, a log2 fold change is attributed to each peptide and protein 
detected (see methods) and using this parameter to filter the data, we found, as expected, an 
overall increase in total tau levels in the CSF of AD patients compared to the non-AD control 
samples analyzed. Overall, a 40% increase was seen, based on the log2 fold change of all un-
phosphorylated tau peptides (n=40) (Figure 2).  Additionally, 11 phosphopeptides were up-
regulated by at least 40% in the CSF of AD patients compared to controls. The significance 
value of this regulation is also incorporated into the data sheet produced, and this can also be 
used to further filter the data. The most significant of the tau phosphopeptides regulated in 
AD compared to controls was a doubly phosphorylated peptide, phosphorylated at Ser231 
and Thr235 (Figure 3 A and B) and a singly phosphorylated peptide, phosphorylated at Ser64 
(Figure 3 C and D) (numbering according to tau441). 
The AD biomarker literature largely focuses on tau phosphorylation at Thr181, and 
measurement of this phosphorylation site by ELISA is one of the three well established CSF 
biomarkers. We detect five different peptides phosphorylated at Thr181 in the whole dataset, 
including singly (Figure 4A) and multiply phosphorylated peptides (Figure 4B). Summing the 
overall change of all unique pThr181 peptides observed results in the expected increase in 
AD CSF levels compared to non-AD controls (Figure 4C). Taking the same approach of 
summing the signal intensities of all of the peptides at each of the phosphosites, we can 
generate an overall tau phosphorylation site map, and see phosphosites that are regulated in 
AD CSF (Figure 5). 
 
DISCUSSION 
Tau in the CSF is believed to be of diagnostic importance, correlating with the severity of 
disease with regard to AD and neurodegeneration. Extensive efforts have been made to 
further characterize the nature of CSF tau, with previous studies largely utilizing immuno-
detection methods, relying on anti-tau antibodies [5, 12]. Immuno-detection approaches have 
had limited success in characterizing the tau in CSF, as the methods are limited by the 
availability, specificity and sensitivity of the antibodies. Furthermore, tau is known to be 
heavily modified by post translational modifications (PTMs), with acetylation, 
phosphorylation, and glycosylation events on numerous residues reported within the protein 
sequence [13]. These PTMs can interfere with the detection of tau by anti-tau antibodies and 
therefore impact on the success of immuno-detection based approaches. Mass spectrometry 
(MS) provides an ideal analytical tool to overcome the specificity limitations of antibody 
based studies but lacks sufficient sensitivity for comprehensive profiling in a complex sample 
such as CSF. Here we have designed and implemented a new MS based method to 
extensively characterize tau in both AD brain tissue and CSF simultaneously to determine 
which tau species are present in the CSF. Using this innovative approach, we have detected 
tau and phospho-tau peptides in the CSF derived from both central and N- and C- terminal 
regions and, in addition, by utilizing TMT® labeling, observations of differential regulation of 
tau peptides in AD compared to non-AD controls have been made.    
Here we used TMT® labeled peptides derived from post mortem brain material to enhance the 
intensity of the equivalent CSF peptides and drive the MS/MS acquisition, allowing the 
detection of low abundant peptides common to the brain and CSF. Although this 
TMTcalibrator™ study was not specifically targeting tau in the AD brain or the CSF, nor 
enriching for tau peptides upstream of MS analysis, peptides covering 86% of the full tau 441 
protein were detectable. 87 different tau peptides common to the brain and the CSF were 
observed, almost half of which were found to be phosphorylated (n=47) representing the 
most extensive characterization of CSF tau reported to date. These peptides covered multiple 
phosphosites, including but not limited to, the widely studied Thr181 residue. 
Phosphorylation of tau at any of the sites reported here could be useful diagnostic 
biomarkers, and could also be used to monitor the efficacy of novel drugs targeting aberrant 
tau phosphorylation, for example kinase inhibitors. Additional tau peptides were also 
measured but were either exclusive to the brain material, or not present in all six CSF 
samples.   
Previous work by groups investigating tau in the CSF has had mixed results, largely due to 
the differences in sample preparation and up-front processing. Studies using MS to detect 
CSF tau have demonstrated some success [6, 7], and the most recently reported work 
identified 18 non-phosphorylated peptides in the CSF using a two-step pre-fractionation 
workflow and monitoring peptides using a spiked heavy labelled recombinant tau protein 
[14]. Until now, this is the most successful attempt at characterizing tau in the CSF. 
TMTcalibrator™ has been designed to avoid immuno-enrichment steps, and does not require 
depletion or filtering of the samples. The combination of fractionation, enrichment for 
phosphopeptides, analysis of both enriched and un-enriched material and a long LC gradient 
has resulted in an extensive coverage of the peptides and proteins present in the AD brain and 
CSF.  
A further benefit of this approach is the use of isobaric TMT® labelling. This has allowed for 
the simultaneous analysis of six CSF samples in one experiment, and allows relative 
quantitation of tau peptides and phosphopeptides in the CSF of AD compared to non-AD 
controls to be made. As expected, the overall tau levels were elevated in the CSF from AD 
patients relative to control, non-AD individuals. We observed a 40% increase in total tau 
levels, and this is in line with previous reports using MS to analyze tau levels [7] but lower 
than the increase found using immunoassays [15]. The levels of 11 tau phosphopeptides were 
also seen to significantly increase in AD by at least 40%, including phosphorylation at 
Thr181. The detection of multiply phosphorylated peptides around the Thr181 residue leads 
us to question the accuracy of the reported immuno-based approaches commonly used to 
measure phospho-tau levels, as phosphorylation at multiple sites is likely to interfere with 
antibody-antigen binding.  
The regulation of the phosphorylation events on tau also showed a relative decrease at some 
phosphosites, most pronounced on Ser285 and Ser289, and down regulation at phosphosites 
has recently been reported in another study [14]. We hypothesize that this could be the result 
of extensive aggregation of the tau proteins in AD resulting in reduced levels in the CSF. 
Alternatively, it is known that O-GlcNAcylation and glycosylation of tau results in a 
reciprocal down regulation of phosphorylation [16], so it may be that modifications to the tau 
peptide sequence that are not captured in this study, such as glycosylation, are either directly 
or indirectly affecting the levels of phosphorylation at certain sites.  
Monitoring an extensive array of tau phosphorylation sites in CSF will likely gain 
importance, particularly as our understanding of their individual and combined roles in 
disease etiology increases and drug development activities shift away from anti-amyloid 
strategies to focus on tau and ways to prevent tangle formation  where there are a number of 
experimental molecules currently in development [17].  
The ability to characterize tau in the CSF is not only important in AD biomarker research, but 
could also have significant impact in the discovery of biomarkers for other tauopathies. The 
TMTcalibrator™ approach could be used to detect the tau species present in the CSF of 
patients with other neurodegenerative tauopathies, as designed here, or also designed to 
directly compare CSF from different diseases, for example, AD CSF compared to 
frontotemporal dementia (FTD) CSF. There is a need for distinct CSF biomarkers of different 
tauopathies as the ELISA CSF total tau measurements cannot distinguish AD from some 
other neurodegenerative diseases; the specificity is only approximately 50% when comparing 
AD to FTD or vascular dementia [18], and it is considered a general marker of axonal 
damage, as seen for example in stroke [19], Creutzfeldt-Jakob disease [20] and traumatic 
brain injury [21]. The ability to detect and relatively quantify phosphorylated tau in the CSF 
is of great benefit as it is likely to be differences in the PTMs of tau that help to better 
distinguish AD and other dementias. In contrast to the poor specificity of total CSF tau, 
phosphorylation at the widely reported Thr181 residue is able to differentiate between AD 
and FTD [5, 18], and it is reasonable to think that alternative phosphosites will be of equal 
importance in tauopathy and neurodegenerative disease biomarker discovery. 
One limitation of this study is the small sample set used. Confirmation of these findings will 
require analysis in a larger cohort of CSF samples, and experimental work is already 
underway to validate the preliminary findings presented here.  
In conclusion, we present here the most comprehensive characterization of CSF tau in AD 
using a new MS technique designed to enhance the detection of low abundant proteins in 
peripheral bodily fluids using an AD brain tissue trigger and numerous phosphorylation sites 
on tau could be detected and quantified in CSF, many of which   have not previously been 
observed. Furthermore, the unique experimental design has allowed for differential regulation 
of these phosphosites between AD and non-AD CSF to be investigated. The results indicate 
that tau in the CSF is extensively modified by phosphorylation events and further studies are 
warranted to determine the value of these modifications as potential biomarkers of disease.    
Analysis of further samples is necessary to confirm disease association, and these 
measurements are ongoing in a more extensive cohort at the time of submission of this 
manuscript.   
Whilst this report has focused exclusively on tau, this was an unbiased study and there were 
over 100 other proteins representing multiple facets of AD pathology that were regulated in 
the disease group CSF samples. Based on these preliminary findings the same 
TMTcalibrator™ approach can be used to provide important pharmacodynamic information 
pertaining to new therapeutic compounds during pre-clinical development and to validate 
translational biomarkers in early human studies. The deployment of TMTcalibrator™ as a 
systems biology tool could therefore offer significant benefits as we strive to find better 
therapeutic strategies to combat dementia.  
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Figure 1. 86% tau coverage was seen in this study with peptides covering all regions of tau 
441. In this image the green highlighted regions represent regions of the protein sequence 
detected. 
 Peptide Sequence Phosphorylation Site 
Number of 
Phosphosites 
akTDHGAEIVykSPVVSGDTSPR S396; 1 
akTDHGAEIVYksPVVsGDTSPR Y?394;S?396;S400; 2 
akTDHGAEIVykSPVVSGDtSPR Y?394;S?396;T?403;S?404; 2 
akTDHGAEIVYksPVVsGDTsPR Y?394;S?396;T403;S404; 3 
esPLQTPTEDGSEEPGSETSDAk S46; 1 
eSPLQTPTEDGSEEPGsETSDAk S61; 1 
iGsTENLk S262; 1 
iGsTEnLkHQPGGGk S?262;T?263; 1 
iGStEnLkHQPGGGk S?262;T?263; 1 
iGStENLkHQPGGGk S?262;T?263; 1 
iGsTENLkHQPGGGk S262; 1 
kLDLSNVQsk S289; 1 
kLDLSnVQsk S289; 1 
lDLsNVQsk S285;S289; 2 
lDLSNVQsk S289; 1 
qAAAQPHTEIPEGtTAEEAGIGDTPSLEDEAAGHVTQA
R T?101;T?102; 1 
sGYSsPGSPGTPGSR S?195;Y?197;S?198; 1 
sGYssPGSPGTPGSR S?195;Y?197;S?198;S?199; 2 
sGySSPGSPGtPGSR S?198;S?199;T205; 2 
sGYSsPGsPGTPGSR S199;S202; 2 
sGYSSPGsPGTPGSR S202; 1 
sGYsSPGSPGTPGSR S202; 1 
skIGsTEnLk S262; 1 
skIGStENLkHQPGGGk S?258;S?262; 1 
skIGsTEnLkHQPGGGk S?258;S?262;T?263; 2 
skIGStEnLkHQPGGGk S?258;S?262;T?263; 1 
skIGsTENLkHQPGGGk S258; 1 
sPVVSGDtSPR S?400;T?403;S?404; 1 
sPVVsGDTSPR S?400;T?403;S?404; 1 
sPVVSGDTsPR T?403;S?404; 1 
sRtPsLPtPPTR T212;S214;T217; 3 
sRTPsLPTPPTREPk T212;S?214;T?217; 2 
sRtPSLPtPPTREPk T212;S214; 2 
sRtPsLPTPPTREPk T212;S214; 2 
sRtPsLPtPPTREPk T212;S214;T217; 3 
tDHGAEIVYksPVVSGDTSPR S396; 1 
tDHGAEIVYkSPVVsGDTsPR S396;S?400;T?403;S?404; 2 
tDHGAEIVYksPVVsGDTSPR S396;S400; 2 
tDHGAEIVykSPVVSGDtSPR S396;T?403;S?404; 2 
tDHGAEIVYksPVVsGDTsPR 
Y?394;S?396;S?400;T?403;S?404
; 3 
tPPAPktPPSSGEPPk T181; 1 
tPPAPktPPSSGEPPkSGDR T181; 1 
tPsLPTPPTREPk S214; 1 
tPSLPtPPTREPk T?212;S?214;T217; 2 
vAVVRtPPkSPSSAk T231; 1 
vAVVRtPPkSPssAk T231;S?235;S?237;S238; 3 
vAVVRtPPkSPSsAk T231;S235; 2 
 
Table 1. List (alphabetical) of phosphorylated tau peptides detected in all samples detailing 
the peptide sequence, phosphorylation site (numbering according to tau 441), and number of 
phosphosites on the peptide. A ? next to the phosphosite denotes a site that cannot be 
determined by the software. 
  
Figure 2. Total tau levels are seen to increase by 40% in the CSF of AD patients 
compared to non-AD control individuals (p=0.049). 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 3. Regulation of phosphotau peptides in seen in the CSF of AD patients compared to 
non-AD controls. Doubly phosphorylated Thr231;Ser235 peptide is shown with the 4-point 
calibrator signal (green) (A) and without the calibrator (B) to better see the regulation 
between control (blue) and AD (red) CSF levels. Similarly, single site phosphorylation at 
Ser64 is shown with (C) and without (D) the calibrator signal. 
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Figure 4. Regulation of tau phosphorylated at Thr181. Singly phosphorylated peptide is shown with (A) and without (B) the calibrator signal to 
better show the increased levels in AD CSF (red) compared to non AD controls (blue), Similarly, triply phosphorylated Thr181;Ser184;Ser185 is 
also shown with (C) and without (D) the calibrator signal. Overall levels of tau phosphorylated at Thr181 were seen to increase in the CSF of 
AD patients compared to non-AD controls (E). Include an F-panel with correlation of pT181 to INNOTEST P-tau181? 

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
  
Figure 5. Tau phosphosite map showing the average log2 fold change in AD CSF compared 
to non-AD controls for each individual phosphosite measured in all 10 TMT® channels.   
 ABBREVIATIONS 
Aβ – Amyloid beta; AD - Alzheimer’s disease; CSF – Cerebrospinal fluid; FTP – 
frontotemporal dementia; IMAC – Immobilized Metal Affinity Columns; LC-MS/MS – 
Liquid chromatography tandem mass spectrometry; MS – Mass spectrometry; NFT – 
Neurofibrillary tangles; PHF – Paired helical filaments; pThr181 – Phosphorylation of 
Threonine 181; PTMs – Post translational modifications; Ser – Serine; Thr – Threonine; 
Tandem Mass Tags® - TMT®; TiO2 – Titanium dioxide. 
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